Gross Margin: 78.21%
Is the gross margin high or low?
The gross margin of 78.21% is in line with its 5-year average of 78.05%, around the middle of its 5-year range (75.38%–80.59%).
As of Sunday, June 28, 2026. 0.09% above its 12-month average of 78.14%.
EW Gross Margin
Reported quarterly gross margin; no daily interpolation.
EW Average Gross Margin Chart
EW Current vs Average Gross Margin Chart
EW Gross Margin Metrics
GROSS MARGIN
78.21%
GROSS MARGIN AVG TTM
78.14%
GROSS MARGIN AVG 3Y
78.36%
GROSS MARGIN AVG 5Y
78.05%
GROSS MARGIN AVG 10Y
76.20%
GROSS MARGIN AVG 15Y
75.32%
GROSS MARGIN AVG 20Y
73.36%
CURRENT VS TTM AVG
+0.09%
CURRENT VS 3Y AVG
-0.19%
CURRENT VS 5Y AVG
+0.20%
CURRENT VS 10Y AVG
+2.63%
CURRENT VS 15Y AVG
+3.83%
CURRENT VS 20Y AVG
+6.60%
EW Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 78.21% | 78.14% | 78.36% | 78.05% |
| Cencora, Inc. (COR)vs › | $55.67B | 3.47% | 3.06% | 3.07% | 2.95% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 3.68% | 3.47% | 3.47% | 3.76% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 46.48% | 45.33% | 44.44% | 44.19% |
| Humana Inc. (HUM)vs › | $46.08B | 14.01% | 14.54% | 16.14% | 17.03% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 62.05% | 61.42% | 60.55% | 59.83% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 84.55% | 85.74% | 85.09% | 84.57% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 70.41% | 65.16% | 63.29% | 62.03% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 53.00% | 53.36% | 52.95% | 53.14% |
| Medline Inc. (MDLN)vs › | $32.87B | 24.04% | 25.55% | 23.71% | 23.71% |
Gross Margin Analysis
Gross Margin
78.2%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for Edwards Lifesciences Corporation (EW)?
- The gross margin for EW stock is 78.21%.
- Is Edwards Lifesciences Corporation's gross margin high or low?
- The gross margin of 78.21% is in line with its 5-year average of 78.05%, around the middle of its 5-year range (75.38%–80.59%).
- What is the TTM average gross margin for Edwards Lifesciences Corporation (EW)?
- The TTM average gross margin for EW stock is 78.14%.
- What is the 3Y average gross margin for Edwards Lifesciences Corporation (EW)?
- The 3Y average gross margin for EW stock is 78.36%.
- What is the 5Y average gross margin for Edwards Lifesciences Corporation (EW)?
- The 5Y average gross margin for EW stock is 78.05%.
- What is the 10Y average gross margin for Edwards Lifesciences Corporation (EW)?
- The 10Y average gross margin for EW stock is 76.20%.
- What is the 15Y average gross margin for Edwards Lifesciences Corporation (EW)?
- The 15Y average gross margin for EW stock is 75.32%.
- What is the 20Y average gross margin for Edwards Lifesciences Corporation (EW)?
- The 20Y average gross margin for EW stock is 73.36%.
EW Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 78.21% |
| 2025-12-31 | 78.30% |
| 2025-09-30 | 77.88% |
| 2025-06-30 | 77.64% |
| 2025-03-31 | 78.65% |
| 2024-12-31 | 78.91% |
| 2024-09-30 | 80.59% |
| 2024-06-30 | 78.51% |
| 2024-03-31 | 78.25% |
| 2023-12-31 | 80.18% |
| 2023-09-30 | 78.11% |
| 2023-06-30 | 79.10% |
| 2023-03-31 | 75.38% |
| 2022-12-31 | 78.08% |
| 2022-09-30 | 78.70% |
| 2022-06-30 | 79.21% |
| 2022-03-31 | 77.14% |
| 2021-12-31 | 76.60% |
| 2021-09-30 | 77.03% |
| 2021-06-30 | 76.31% |
| 2021-03-31 | 76.34% |
| 2020-12-31 | 75.25% |
| 2020-09-30 | 74.85% |
| 2020-06-30 | 73.42% |
| 2020-03-31 | 75.97% |
| 2019-12-31 | 74.84% |
| 2019-09-30 | 72.10% |
| 2019-06-30 | 70.99% |
| 2019-03-31 | 75.89% |
| 2018-12-31 | 75.84% |
| 2018-09-30 | 75.70% |
| 2018-06-30 | 75.26% |
| 2018-03-31 | 74.06% |
| 2017-12-31 | 73.54% |
| 2017-09-30 | 73.66% |
| 2017-06-30 | 75.18% |
| 2017-03-31 | 75.31% |
| 2016-12-31 | 72.61% |
| 2016-09-30 | 73.21% |
| 2016-06-30 | 73.33% |
| 2016-03-31 | 74.14% |
| 2015-12-31 | 73.79% |
| 2015-09-30 | 76.17% |
| 2015-06-30 | 74.29% |
| 2015-03-31 | 76.96% |
| 2014-12-31 | 74.05% |
| 2014-09-30 | 72.32% |
| 2014-06-30 | 73.71% |
| 2014-03-31 | 72.07% |
| 2013-12-31 | 72.85% |
| 2013-09-30 | 73.83% |
| 2013-06-30 | 75.83% |
| 2013-03-31 | 75.40% |
| 2012-12-31 | 75.36% |
| 2012-09-30 | 75.06% |
| 2012-06-30 | 73.07% |
| 2012-03-31 | 72.28% |
| 2011-12-31 | 72.20% |
| 2011-09-30 | 69.57% |
| 2011-06-30 | 70.36% |
| 2011-03-31 | 71.12% |
| 2010-12-31 | 71.08% |
| 2010-09-30 | 72.54% |
| 2010-06-30 | 72.51% |
| 2010-03-31 | 71.04% |
| 2009-12-31 | 70.67% |
| 2009-09-30 | 69.76% |
| 2009-06-30 | 69.63% |
| 2009-03-31 | 69.06% |
| 2008-12-31 | 68.10% |
| 2008-09-30 | 65.45% |
| 2008-06-30 | 65.51% |
| 2008-03-31 | 65.33% |
| 2007-12-31 | 66.01% |
| 2007-09-30 | 65.30% |
| 2007-06-30 | 65.26% |
| 2007-03-31 | 64.71% |
| 2006-12-31 | 63.33% |
| 2006-09-30 | 64.67% |
| 2006-06-30 | 64.20% |
| 2006-03-31 | 63.81% |
| 2005-12-31 | 64.12% |
| 2005-09-30 | 62.27% |
| 2005-06-30 | 62.08% |
| 2005-03-31 | 61.38% |
| 2004-12-31 | 61.54% |
| 2004-09-30 | 60.90% |
| 2004-06-30 | 60.61% |
| 2004-03-31 | 58.00% |
| 2003-12-31 | 58.14% |
| 2003-09-30 | 57.84% |
| 2003-06-30 | 58.86% |
| 2003-03-31 | 58.07% |
| 2002-12-31 | 57.80% |
| 2002-09-30 | 57.84% |
| 2002-06-30 | 56.94% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian